Cargando…

Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab

Purpose: To investigate the alterations of retinal vessel diameters in patients with macular edema secondary to retinal vein occlusion (RVO), before and after treatment with intravitreal ranibizumab. Methods: Digital retinal images were obtained from 16 patients and retinal vessel diameters were mea...

Descripción completa

Detalles Bibliográficos
Autores principales: Aissopou, Evaggelia, Protogerou, Athanasios, Theodossiadis, Panagiotis, Sfikakis, Petros P., Chatziralli, Irini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963538/
https://www.ncbi.nlm.nih.gov/pubmed/36836585
http://dx.doi.org/10.3390/jpm13020351
_version_ 1784896276419051520
author Aissopou, Evaggelia
Protogerou, Athanasios
Theodossiadis, Panagiotis
Sfikakis, Petros P.
Chatziralli, Irini
author_facet Aissopou, Evaggelia
Protogerou, Athanasios
Theodossiadis, Panagiotis
Sfikakis, Petros P.
Chatziralli, Irini
author_sort Aissopou, Evaggelia
collection PubMed
description Purpose: To investigate the alterations of retinal vessel diameters in patients with macular edema secondary to retinal vein occlusion (RVO), before and after treatment with intravitreal ranibizumab. Methods: Digital retinal images were obtained from 16 patients and retinal vessel diameters were measured before and three months after treatment with intravitreal ranibizumab with validated software to determine central retinal arteriolar and venular equivalents, as well as arteriolar to venular ratio. Results: In 17 eyes of 16 patients with macular edema secondary to RVO (10 with branch RVO and 6 with central RVO) aged 67 ± 10.2 years, we found that diameters of both retinal arterioles and venules were significantly decreased after intravitreal ranibizumab treatment. Specifically, the central retinal arteriolar equivalent was 215.2 ± 11.2 μm at baseline and 201.2 ± 11.1 μm at month 3 after treatment (p < 0.001), while the central retinal venular equivalent was 233.8 ± 29.6 μm before treatment versus 207.6 ± 21.7 μm at month 3 after treatment (p < 0.001). Conclusions: A significant vasoconstriction in both retinal arterioles and venules in patients with RVO was found at month 3 after intravitreal ranibizumab treatment compared to baseline. This could be of clinical importance, since the degree of vasoconstriction might be an early marker of treatment efficacy, compatible with the idea that hypoxia is the major trigger of VEGF in RVO. Further studies should be conducted to confirm our findings.
format Online
Article
Text
id pubmed-9963538
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99635382023-02-26 Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab Aissopou, Evaggelia Protogerou, Athanasios Theodossiadis, Panagiotis Sfikakis, Petros P. Chatziralli, Irini J Pers Med Communication Purpose: To investigate the alterations of retinal vessel diameters in patients with macular edema secondary to retinal vein occlusion (RVO), before and after treatment with intravitreal ranibizumab. Methods: Digital retinal images were obtained from 16 patients and retinal vessel diameters were measured before and three months after treatment with intravitreal ranibizumab with validated software to determine central retinal arteriolar and venular equivalents, as well as arteriolar to venular ratio. Results: In 17 eyes of 16 patients with macular edema secondary to RVO (10 with branch RVO and 6 with central RVO) aged 67 ± 10.2 years, we found that diameters of both retinal arterioles and venules were significantly decreased after intravitreal ranibizumab treatment. Specifically, the central retinal arteriolar equivalent was 215.2 ± 11.2 μm at baseline and 201.2 ± 11.1 μm at month 3 after treatment (p < 0.001), while the central retinal venular equivalent was 233.8 ± 29.6 μm before treatment versus 207.6 ± 21.7 μm at month 3 after treatment (p < 0.001). Conclusions: A significant vasoconstriction in both retinal arterioles and venules in patients with RVO was found at month 3 after intravitreal ranibizumab treatment compared to baseline. This could be of clinical importance, since the degree of vasoconstriction might be an early marker of treatment efficacy, compatible with the idea that hypoxia is the major trigger of VEGF in RVO. Further studies should be conducted to confirm our findings. MDPI 2023-02-17 /pmc/articles/PMC9963538/ /pubmed/36836585 http://dx.doi.org/10.3390/jpm13020351 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Aissopou, Evaggelia
Protogerou, Athanasios
Theodossiadis, Panagiotis
Sfikakis, Petros P.
Chatziralli, Irini
Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title_full Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title_fullStr Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title_full_unstemmed Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title_short Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
title_sort alterations in retinal vessel diameters in patients with retinal vein occlusion before and after treatment with intravitreal ranibizumab
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963538/
https://www.ncbi.nlm.nih.gov/pubmed/36836585
http://dx.doi.org/10.3390/jpm13020351
work_keys_str_mv AT aissopouevaggelia alterationsinretinalvesseldiametersinpatientswithretinalveinocclusionbeforeandaftertreatmentwithintravitrealranibizumab
AT protogerouathanasios alterationsinretinalvesseldiametersinpatientswithretinalveinocclusionbeforeandaftertreatmentwithintravitrealranibizumab
AT theodossiadispanagiotis alterationsinretinalvesseldiametersinpatientswithretinalveinocclusionbeforeandaftertreatmentwithintravitrealranibizumab
AT sfikakispetrosp alterationsinretinalvesseldiametersinpatientswithretinalveinocclusionbeforeandaftertreatmentwithintravitrealranibizumab
AT chatziralliirini alterationsinretinalvesseldiametersinpatientswithretinalveinocclusionbeforeandaftertreatmentwithintravitrealranibizumab